Bone metastasis as a prognostic factor in breast cancer patients with liver metastasis given OK-432-combined adoptive immunotherapy via the hepatic artery.
The outcome in 31 patients with liver metastases from breast cancer given OK-432-combined adoptive immunotherapy via the hepatic artery was analyzed. Patients received intraarterial OK-432, a streptococcal preparation, followed by the transfer of autologous lymphocytes cultured with autologous tumor extract and interleukin-2 for 9-13 days. Liver lesions were evaluable in 11 of the 12 patients with bone metastasis (group A) and in 16 of the 19 patients without bone metastasis (group B). Complete response (CR) in the liver was attained in 8 patients in group A, but in only 1 in group B (p < 0.01). In group A, radiological features of all metastatic foci of bone improved after CR in the liver. Moreover, the median survival time (MST) of group A (20 months) was longer (p = 0.06) than that of group B patients with extra-hepatic metastasis (n = 12; MST = 6 months), while group B patients with liver metastasis alone (n = 7) showed a MST similar to that of group A. Thus, loco-regional immunotherapy via the hepatic artery was found to be useful in controlling both liver and bone metastasis from breast cancer. Moreover, in breast cancer patients with liver metastasis, bone metastasis appears to be a prognostic factor associated with good response to this immunotherapy.
Kan
N
N
First Department of Surgery, Faculty of Medicine, Kyoto University, Japan.
Yamasaki
S
S
Kodama
H
H
Okino
T
T
Ichinose
Y
Y
Moriguchi
Y
Y
Li
L
L
Sugie
T
T
Imamura
M
M
D000328:Adult; D001859:Bone Neoplasms / Q000556:secondary* / Q000628:therapy; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006499:Hepatic Artery; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000401:mortality; D007269:Injections, Intra-Arterial; D007376:Interleukin-2 / Q000494:pharmacology; D015979:Killer Cells, Lymphokine-Activated; D008113:Liver Neoplasms / Q000556:secondary* / Q000628:therapy; D008213:Lymphocyte Activation / Q000187:drug effects; D008214:Lymphocytes / Q000187:drug effects; D008875:Middle Aged; D017063:Outcome Assessment, Health Care; D010844:Picibanil / Q000627:therapeutic use*; D011379:Prognosis; D012189:Retrospective Studies
D007376:Interleukin-2; D010844:Picibanil